CZ 112

Drug Profile

CZ 112

Alternative Names: 9-Nitrocamptothecin propionate; Rubitecan prodrug

Latest Information Update: 20 Apr 2011

Price : $50

At a glance

  • Originator The Stehlin Foundation for Cancer Research
  • Developer SuperGen
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Jul 2004 This compound is still in active development
  • 17 Feb 2000 A preclinical study has been added to the pharmacodynamics section
  • 05 Jan 1999 Phase-I clinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top